censavudine
Small moleculeexperimental
Censavudine is an investigational new drug being developed by Bristol Myers-Squibb for the treatment of HIV infection. It was originally developed at Yale University. It is still in an investigational phase of development as of 2023. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2011 (NCT01489046)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Reverse transcriptaseINHIBITOR
Reverse transcriptase inhibitor
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C#C[C@@]1(CO)C=C[C@H](n2cc(C)c(=O)[nH]c2=O)O1- Mol. weight
- 248.24 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCensavudine ↗
- ChEMBLCHEMBL124363 ↗
Also known as
- 2',3'-didehydro-3'-deoxy-4'-c-ethynylthymidine
- 4'-ed4t
- 4'-ethynylstavudine
- 4'-ethynylstavudine
- 4'-ethynylstavudine
- 4'-ethynyl stavudine
- 4'-ethynyl stavudine
- bms-986001
- bms-986001
- bms-986001
- censavudine
- censavudine
- censavudine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01489046 | Phase 2 | Feb 1, 2011 | Bristol-Myers Squibb |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 1 | 1 | 1 | 2011 |
1 organizations
Page 1 / 1